GE's Clarient Purchase Heightens Company's Focus on Tests for Cancer Drug Personalization

GE Healthcare continues to grow its presence in personalized medicine through its recent purchase of Clarient, which has assets in oncology molecular diagnostics and companion tests.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.